Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue.

Johansen PB, Segev Y, Landau D, Phillip M, Flyvbjerg A

Experimental diabesity research1 Apr 2003Cited by 6 (Europe PMC)

PMID14630569PMCIDPMC2478601DOI10.1155/edr.2003.73PepBankPUB-14630569

Summary

The growth hormone (GH) and insulin-like growth factor I (IGF-I) axis were studied in streptozotocin (STZ) diabetic and nondiabetic female mice following intravenous (IV) injection of the GH secretagogue (GHS) ipamorelin or saline. On day 14, blood samples were obtained before and 10 minutes after the injection. Livers were removed and frozen for determination of the mRNA expressions of the GH receptor, GH-binding protein, and IGF-I, and hepatic IGF-I peptide. Serum samples were analyzed for GH and IGF-I. Following ipamorelin injection, the GH levels were found to be 150 +/- 35 microg/L and 62 +/- 11 microg/L in the diabetic compared to the nondiabetic mice (P <.05). Serum IGF-I levels were lower in diabetic than in nondiabetic animals, and rose after stimulation only in the nondiabetic animals. Furthermore, hepatic GH resistance and IGF-I mRNA levels and IGF-I peptide were increased in nondiabetic animals in response to GH stimulation, whereas the low levels per se of all these parameters in diabetic mice were unaffected. The study shows that STZ diabetic mice demonstrate a substantial part of the clinical features of type 1 diabetes in humans, including GH hypersecretion and GH resistance. Accordingly, it is proposed that STZ diabetic mice may be a better model of the perturbations of the GH/IGF-I axis in diabetes than STZ diabetic rats.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice, GH levels after ipamorelin injection were higher in diabetic than in nondiabetic animals.
In plain wordsIn mice, growth hormone levels after an ipamorelin injection were higher in diabetic mice than in non-diabetic mice.
Peptide
Ipamorelin
Outcome
IncreaseSerum GH after ipamorelin, diabetic versus nondiabetic mice
Study
mousen: not reported in source
streptozotocin diabetic and nondiabetic female mice
Comparator
Nondiabetic mice
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · intravenousAs given in this study (mouse).
Measurements
Serum GH after ipamorelin
150 microg/L
diabetic mice
Serum GH after ipamorelin
62 microg/L
nondiabetic mice
Source sentences
Summary
Following ipamorelin injection, the GH levels were found to be 150 +/- 35 microg/L and 62 +/- 11 microg/L in the diabetic compared to the nondiabetic mice (P <.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone (GH) and insulin-like growth factor I (IGF-I) axis were studied in streptozotocin (STZ) diabetic and nondiabetic female mice following intravenous (IV) injection of the GH secretagogue (GHS) ipamorelin or saline.
Show in the study text Report a problemFND-1463056901
02AnimalAnimal study (in vivo)Efficacy outcome
In mice, serum IGF-I rose after ipamorelin only in nondiabetic animals and stayed low in diabetic animals.
In plain wordsIn mice, ipamorelin raised IGF-I only in non-diabetic mice, not in diabetic mice.
Peptide
Ipamorelin
Outcome
MixedSerum IGF-I after ipamorelin stimulation
Study
mousen: not reported in source
streptozotocin diabetic and nondiabetic female mice
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · intravenousAs given in this study (mouse).
Source sentences
Summary
Serum IGF-I levels were lower in diabetic than in nondiabetic animals, and rose after stimulation only in the nondiabetic animals.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone (GH) and insulin-like growth factor I (IGF-I) axis were studied in streptozotocin (STZ) diabetic and nondiabetic female mice following intravenous (IV) injection of the GH secretagogue (GHS) ipamorelin or saline.
Show in the study text Report a problemFND-1463056902
03AnimalAnimal study (in vivo)Mechanism
In mice, hepatic GH resistance increased after GH stimulation by ipamorelin in nondiabetic animals and was unaffected in diabetic animals.
In plain wordsIn mice, ipamorelin increased a liver marker of GH resistance in non-diabetic mice but not in diabetic mice.
Peptide
Ipamorelin
Outcome
MixedHepatic GH resistance
Study
mousen: not reported in source
streptozotocin diabetic and nondiabetic female mice
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · intravenousAs given in this study (mouse).
Source sentences
Summary
Furthermore, hepatic GH resistance and IGF-I mRNA levels and IGF-I peptide were increased in nondiabetic animals in response to GH stimulation, whereas the low levels per se of all these parameters in diabetic mice were unaffected.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone (GH) and insulin-like growth factor I (IGF-I) axis were studied in streptozotocin (STZ) diabetic and nondiabetic female mice following intravenous (IV) injection of the GH secretagogue (GHS) ipamorelin or saline.
Show in the study text Report a problemFND-1463056903
04AnimalAnimal study (in vivo)Mechanism
In mice, hepatic IGF-I mRNA increased after GH stimulation by ipamorelin in nondiabetic animals and was unaffected in diabetic animals.
In plain wordsIn mice, ipamorelin raised liver IGF-I mRNA in non-diabetic mice but not in diabetic mice.
Peptide
Ipamorelin
Outcome
MixedHepatic IGF-I mRNA
Study
mousen: not reported in source
streptozotocin diabetic and nondiabetic female mice
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · intravenousAs given in this study (mouse).
Source sentences
Summary
Furthermore, hepatic GH resistance and IGF-I mRNA levels and IGF-I peptide were increased in nondiabetic animals in response to GH stimulation, whereas the low levels per se of all these parameters in diabetic mice were unaffected.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone (GH) and insulin-like growth factor I (IGF-I) axis were studied in streptozotocin (STZ) diabetic and nondiabetic female mice following intravenous (IV) injection of the GH secretagogue (GHS) ipamorelin or saline.
Show in the study text Report a problemFND-1463056904
05AnimalAnimal study (in vivo)Mechanism
In mice, hepatic IGF-I peptide increased after GH stimulation by ipamorelin in nondiabetic animals and was unaffected in diabetic animals.
In plain wordsIn mice, ipamorelin raised liver IGF-I peptide in non-diabetic mice but not in diabetic mice.
Peptide
Ipamorelin
Outcome
MixedHepatic IGF-I peptide
Study
mousen: not reported in source
streptozotocin diabetic and nondiabetic female mice
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · intravenousAs given in this study (mouse).
Source sentences
Summary
Furthermore, hepatic GH resistance and IGF-I mRNA levels and IGF-I peptide were increased in nondiabetic animals in response to GH stimulation, whereas the low levels per se of all these parameters in diabetic mice were unaffected.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth hormone (GH) and insulin-like growth factor I (IGF-I) axis were studied in streptozotocin (STZ) diabetic and nondiabetic female mice following intravenous (IV) injection of the GH secretagogue (GHS) ipamorelin or saline.
Show in the study text Report a problemFND-1463056905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.